Clinical trials: Bone and Bones
Osteoporosis
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
The study is designed as a retrospective, multicenter study for subjects previously treated with the AGN1 LOEP Kit in the proximal femur as part of standard hospital practice. This will be a non-randomized and non-blinded study.
- Trial name
- NCT07594639
- Testing
- AGN1 LOEP
- Where
- Belgium
- Volunteers
- 305 people
- Sponsor
- AgNovos Healthcare, LLC
Osteopenia
Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090)
Both tibolone and raloxifene have been demonstrated to prevent postmenopausal bone loss. During treatment with tibolone bone mineral density (BMD) of the spine has been shown to be increased between 1.8 and 5.8 % above baseline…
- Trial name
- STEP (NCT00431431)
- Testing
- tibolone, raloxifen
- Volunteers
- 324 people
- Sponsor
- Organon and Co
Bone Marrow Failure Syndromes, Aplastic Anemias
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
This is a multicenter, open-label, Phase 1/2 basket study to evaluate the safety and efficacy of Dibotatug (DR-01) in adults with Bone Marrow Failure syndromes.
- Conditions
- Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
- Trial name
- BMF (NCT07712562)
- Testing
- Dibotatug (DR-01)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dren Bio
Contraception, Change in Bone Mineral Density
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
This study will be in two parts, Part A and Part B. The primary objective of Part A is to evaluate the contraceptive efficacy of LPRI-CF113.
- Trial name
- NCT05461573
- Testing
- Drospirenone
- Where
- 47 sites in United States, Canada
- Volunteers
- 1,542 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Chronic Myeloid Leukemia, Chronic Phase
Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib
A retrospective, non-interventional cohort study design using data obtained from the Flatiron Health oncology electronic health record (EHR)-derived de-identified database, was used to address the study objectives.
- Trial name
- NCT06516029
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Novartis
Radiculopathy, Cervical, Myelopathy Cervical
Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease
The goal of this pilot clinical trial is to test the safety and preliminary performance of the ZetaFuse Bone Graft in patient requiring fusion of the C3-C7 vertebral bones due to pain or loss of neurological function.
- Conditions
- Radiculopathy, Cervical, Myelopathy Cervical, Neurological Abnormality, Disc Disease
- Trial name
- NCT05971329
- Testing
- Cervical Fusion (ZetaFuse™ Bone Graft)
- Where
- 2 sites in Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Zetagen Therapeutics, Inc
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with HR-MDS or CMML, or low-blast AML.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- NCT02610777
- Testing
- Azacitidine, Pevonedistat
- Where
- 59 sites in United States, Belgium and 10 more
- Volunteers
- 120 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Osteoporosis, Postmenopausal
Satisfaction and Compliance of Risedronate in PMO
Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women.
- Trial name
- NCT00549965
- Testing
- Risedronate Sodium
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Sanofi
Ewing's Sarcoma, Ewing Family of Tumors
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
- Conditions
- Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- NCT02736565
- Testing
- pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gradalis, Inc.
Prostate Cancer, Osteoporosis
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer.
- Conditions
- Prostate Cancer, Osteoporosis, Fractures
- Trial name
- NCT00129142
- Testing
- Toremifene Citrate
- Where
- 155 sites in United States, Mexico
- Volunteers
- 1,200 people
- Sponsor
- GTx
Chronic Myelogenous Leukemia, Malignant Melanoma
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A®) in prior clinical…
- Conditions
- Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma
- Trial name
- NCT02829775
- Testing
- Pegylated Interferon Alfa-2a, Recombinant Interferon Alfa 2a
- Where
- 8 sites in Bulgaria, Canada and 5 more
- Volunteers
- 9 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.
- Trial name
- NCT00324220
- Testing
- MGCD0103
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Mirati Therapeutics Inc.
Psoriatic Arthritis
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
- Trial name
- NCT02319759
- Testing
- Guselkumab, Ustekinumab
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Janssen Research & Development, LLC
Radial Head Fractures
A Study of Participants Undergoing Radial Head Replacement Using the DePuy Synthes Radial Head Replacement System for Partial Replacement of the Elbow Joint
The purpose of this study is to establish survivorship defined by the cumulative incidence of revision over the first 6 months post-implantation.
- Trial name
- NCT05415592
- Testing
- DePuy Synthes Radial Head Replacement System
- Where
- 4 sites in United States, United Kingdom
- Sponsor
- DePuy Synthes Products, Inc.
Prostate Cancer
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
- Trial name
- NCT01302041
- Testing
- Enzalutamide
- Where
- 12 sites in Belgium, Czechia and 2 more
- Volunteers
- 67 people
- Sponsor
- Astellas Pharma Inc
Psoriatic Arthritis
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
- Trial name
- OPAL BEYOND (NCT01882439)
- Testing
- Tofacitinib
- Where
- 125 sites in United States, Australia and 12 more
- Volunteers
- 395 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
This study aims to provide a holistic assessment of patients receiving etanercept in a real-world setting.
- Trial name
- NCT00544557
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,715 people
- Sponsor
- Pfizer
Sport Medicine
ATI Evidence-based Guide Investigating Medical and Preventative Services
To use existing standard-of-care documentation in a sports medicine electronic medical record (EMR) to evaluate patient characteristics, interventions delivered, utilization management, and clinical outcomes in routine sports…
- Trial name
- NCT04050319
- Testing
- Screening and diagnosis if injured
- Where
- United States
- Volunteers
- 550,000 people, healthy volunteers welcome
- Sponsor
- ATI Holdings, LLC
Myelofibrosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary…
- Trial name
- NCT05371964
- Testing
- Imetelstat sodium, Ruxolitinib
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Geron Corporation
Axial Psoratic Arthritis
Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 150 mg or 300 mg in the management of axial manifestations in PsA patients who have failed to respond to at least 2 non-steroidal…
- Trial name
- MAXIMISE (NCT02721966)
- Testing
- Secukinumab
- Where
- 94 sites in Belgium, Bulgaria and 16 more
- Volunteers
- 503 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.